Drainage device implantation riskier than trabeculectomy

Article

The risk of adverse events following implantation of a glaucoma drainage device (GDD) is higher than the risk following either primary trabeculectomy (PT) or trabeculectomy with scarring (TS), according to results of a study published in the July 2008 issue of Ophthalmology.

The risk of adverse events following implantation of a glaucoma drainage device (GDD) is higher than the risk following either primary trabeculectomy (PT) or trabeculectomy with scarring (TS), according to results of a study published in the July 2008 issue of Ophthalmology.

Frank A. Sloan, PhD of the Center for Health Policy, Duke University, North Carolina, US and colleagues conducted a retrospective, longitudinal cohort analysis of subjects (aged ≥68 years) undergoing PT, TS or GDD implantation between 1994–2003, with follow-up to 2005, to determine rates of postoperative adverse outcomes.

Retinal detachment, endophthalmitis and suprachoroidal haemorrhage were classified as severe complications; choroidal detachment, corneal oedema and hypotony were classified as less serious outcomes.

At the one year follow-up point, severe adverse events in the GDD implantation, TS and PT subject groups were 2.0%, 1.3% and 0.6%, respectively; rates of subjects developing less serious adverse events and low vision/blindness were higher in the GDD group than in the TS and PT groups. After controlling for demographic factors, differences were reduced but not to a statistically significant degree.

Regardless of controlling for demographic factors, the rates of adverse events across the spectrum of severity were slightly higher for patients undergoing GDD implantation than TS or PT surgery.

Recent Videos
Patrick C. Staropoli, MD, discusses clinical characterisation of Hexokinase 1 (HK1) mutations causing autosomal dominant pericentral retinitis pigmentosa
Richard B. Rosen, MD, discusses his ASRS presentation on illuminating subclinical sickle cell activities using dynamic OCT angiography
ASRS 2024: Socioeconomic barriers and visual outcomes in patients with rhegmatogenous retinal detachments, from Sally S. Ong, MD
Ashkan Abbey, MD, speaks about his presentation on the the CALM registry study, the 36-month outcomes of real world patients receiving fluocinolone acetonide 0.18 mg at the annual ASRS meeting in Stockholm, Sweden.
Nikoloz Labauri, MD, FVRS, speaks at the 2024 ASRS meeting about suspensory macular buckling as a novel technique for addressing myopic traction maculopathy
Jordana Fein, MD, MS, speaks with Modern Retina about the IOP outcomes with aflibercept 8 mg and 2 mg in patients with DME through week 48 of the phase 2/3 PHOTON trial at the annual ASRS meeting in Stockholm, Sweden.
John T. Thompson, MD, discusses his presentation at ASRS, Long-Term Results of Macular Hole Surgery With Long-Acting Gas Tamponade and Internal Limiting Membrane Peeling
ASRS 2024: Michael Singer, MD, shares 100-week results from the RESTORE trial
© 2024 MJH Life Sciences

All rights reserved.